Clinuvel Pharmaceuticals achieved positive results from a Phase III trial of Scenesse in patients with erythropoietic protoporphyria (EPP), showing that the drug has the ability to reduce and prevent painful phototoxic reactions. EPP is characterized by intolerable pain associated with skin burns, blisters and scars when exposed to normal levels of light and sun. It is estimated that 10,000 individuals worldwide are afflicted with EPP. Results from the study showed that Scenesse treatment sig...